Plasma Metabolomic Profiling in Essential Thrombocythemia: Pathway-Level Alterations and Their Relationship to Treatment Status, Platelet Count, and JAK2V617F Status
Authors:
- Batuhan ErdoğduBEBatuhan Erdoğdu
- Murat YıldırımMYMurat Yıldırım
- Selim SayınSSSelim Sayın
- Mustafa ÇelebierMÇMustafa Çelebier
- Ozan KaplanOKOzan Kaplan
- Emine KoçEKEmine Koç
- Merve NenniMNMerve Nenni
- Duygu Eneş GöktanDGDuygu Eneş Göktan
- Mustafa GüneyMGMustafa Güney
- Gül Yavuz ErmişGEGül Yavuz Ermiş
- Duygu GülDGDuygu Gül
- Ebru Kılıç GüneşEGEbru Kılıç Güneş
Open Access
- 23 October 2026
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 16 (11) , 809
Abstract
Background/Objectives: Essential thrombocythemia (ET) is a JAK-STAT-driven myeloproliferative neoplasm with an incompletely defined metabolic phenotype. This study aimed to characterize the plasma metabolome of ET and to determine whether it differs according to JAK2V617F status, platelet count (≥450 vs. 1.5 or 2Y = 0.96; nested cross-validation Q2 = 0.91; permutation p = 0.001). Nineteen metabolites met the criteria: seven Level 1 identifications (succinate, an aminobutyrate isomer, uridine and N-acetylphenylalanine higher; proline, glucuronolactone and quinaldate lower in ET) and twelve Level 3 candidates dominated by platelet-derived eicosanoids, including 11-dehydro-thromboxane B2 (detected in 26% of controls and 99% of patients) and thromboxane B2 (4% and 84%), prostaglandin D2/E2 and B1/A1 isomers, a hydroxy-docosahexaenoic acid isomer, and corticosteroid intermediates. Reactome over-representation analysis, which rests mainly on Level 3 candidates, ranked synthesis of prostaglandins and thromboxanes and arachidonate metabolism highest (FDR 7 × 10−5), followed by fatty acid metabolism, pyrimidine catabolism and, on the basis of Level 3 candidates only, mineralocorticoid biosynthesis. The signature was similar in direction across cytoreductive-therapy, platelet-count and JAK2V617F strata. Conclusions: These exploratory data describe a plasma metabolite signature of aspirin-treated ET dominated by platelet-derived eicosanoids, together with changes in succinate and pyrimidine-related metabolites and candidate changes in corticosteroid intermediates; because aspirin exposure and disease status were fully confounded, the signature requires confirmation with targeted methods in independent cohorts.Keywords
This publication has 64 references indexed in Scilit:
- Essential ThrombocythemiaJAMA, 2025
- Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trialAmerican Journal of Hematology, 2024
- Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2024
- Arachidonic acid metabolism in health and diseaseMedcomm, 2023
- Association of serum cortisol and cortisone levels and risk of recurrence after endocrine treatment in breast cancerClinical and Experimental Medicine, 2023
- Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential ThrombocythemiaClinical Pharmacology & Therapeutics, 2021
- Improved batch correction in untargeted MS-based metabolomicsMetabolomics, 2016
- Targeted MetabolomicsCurrent Protocols in Molecular Biology, 2012
- Proposed minimum reporting standards for chemical analysisMetabolomics, 2007